Previous studies indicated that signaling through lymphocyte activation gene-3 (LAG-3), a MHC class II ligand, induced by multivalent anti-receptor antibodies led to unresponsiveness to TCR stimulation. Here, lateral distribution of the LAG-3 molecules and its topological relationship (mutual proximity) to the TCR, CD8, CD4, and MHC class I and II molecules were studied in the plasma membrane of activated human T cells in co-capping experiments and conventional fluorescence microscopy. Following TCR engagement by either TCR-specific mAb or MHC-peptide complex recognition in T-B cell conjugates, LAG-3 was found to be specifically associated with the CD3-TCR complex. Similarly, following CD8 engagement LAG-3 and CD8 were co-distributed on the cell surface while only a low percentage of CD4-capped cells displayed LAG-3 co-caps. In addition, LAG-3 was found to be associated with MHC class II (i.e. DR, DP and DQ) and partially with MHC class I molecules. The supramolecular assemblies described here between LAG-3, CD3, CD8 and MHC class II molecules may result from an organization in raft microdomains, a phenomenon known to regulate early events of T cell activation.
Introduction
Lymphocyte activation is a central event in the generation APC, which are thought to trigger the same biochemical pathways. of an immune response, resulting in clonal expansion of immunocompetent cells and their acquisition of effector funcThe co-receptor molecules, CD4 and CD8, as well as other surface antigens, such as CD38, CD40 ligand or CD28 tions (1) . Activation is accompanied by the modification of the expression of several genes that encode molecules (1) (2) (3) (4) , potentiate signal one delivered by the TCR and increase lymphocyte sensitivity to the antigen. Thus, these molecules involved in cell proliferation, effector functions and cell-cell interactions, which are defined as very early, early and late are crucial for triggering the immune response in vivo when the antigen concentration is low or when the antigen is a activation molecules according to their expression kinetics. T cell activation depends on the complex integration of signals weak agonist. Such potentiation is generally thought to result from the ability of the TCR and the TCR-associated receptors that are delivered by multiple antigen receptors that are serially triggered by physiological membrane-associated ligands on to cluster at the contacts between T cells and APC during antigen-specific interactions. Indeed, some anti-TCR antibodthe antigen-presenting cell (APC) (i.e. peptide bound to MHC molecules). Most receptor-proximal activation events have ies are very potent at activating T cells even though they do not efficiently cross-link the TCR, e.g. by promoting a closer nonetheless been identified using multivalent anti-receptor antibodies, eliminating the need to use the more complex association between CD4 and TCR (5). Fig. 1 . LAG-3 and TCR co-cap after TCR engagement with mAb. extent, to CD4 molecules. CD8 and CD4 caps were induced by TCR-polarized distribution on PHA blasts was induced by crosspreincubating PHA blasts with OKT8 (IgG2a) (A and B) or OKT4 linking the TCR molecules with BMA 031 mAb (IgG2b) plus FITC-(IgG2b) (C) plus appropriate FITC-labeled goat anti-mouse subclasslabeled anti-IgG2b goat anti-mouse for 5 min at 37°C. LAG-3 (A), specific Ig for 15 min at 37°C. Shown are LAG-3 (A) and LFA-1 (B) LFA-1 (B) and CD4 (C) distribution was analyzed on the surface of distribution on mAb-induced CD8-capped cells and LAG-3 TCR-capped activated T cells with 17B4 (IgG 1 ), C4C8D9 (IgG1) and distribution on mAb-induced CD4-capped cells (C). An optical section 13B8-2 (IgG1) plus the corresponding Texas Red-labeled goat antiof two examples of cells for each case is shown. mouse subclass-specific Ig. An optical section of two examples of cells for each case is shown.
Fig. 2. LAG-3 is associated with CD8 molecules and, to a lesser
activation, TSA-1 (13), CTLA-4 (14) and CD5 (15) inhibit T cell responses. Over the years, several molecules have been found to be associated to CD3-TCR complexes. Some molecules are Lymphocyte activation gene-3 (LAG-3) is a T and NK cellspecific activation antigen (16) which, like CD4, is a ligand constitutively expressed antigens such as the CD4 (5,6) and CD8 (7) co-receptors, CD5 (8), the adaptator protein termed for MHC class II molecules (17,18). LAG-3 signaling induced by multivalent anti-receptor antibodies leads to unrespon-TCR interacting molecule (TRIM) (9) or the glycosylphosphatidylinositol-anchored membrane protein termed thymic shared siveness to TCR stimulation with inhibition of both proliferation and cytokine secretion, and down-regulation of TCR expresantigen-1 (TSA-1) (10). Other are activation antigens such as CTLA-4 (11) and H4 (12). Whereas the CD4 and CD8 cosion (19). LAG-3 cross-linking inhibits calcium response to CD3 stimulation only in conditions where LAG-3 and CD3 are receptors have generally been shown to potentiate T cell co-engaged. Unexpectedly, this MHC class II ligand LAG-3 1 were used as ascitic fluids. 17B4 (IgG1) mAb recognized is expressed at higher levels on CD8 ϩ than on CD4 ϩ T cells the LAG-3.1 epitope on the extra loop of the first IgSF domain (20). This difference in expression patterns between the two of LAG-3 (17). 13B8-2 (IgG1) specific for CD4, BMA031 T cell subsets may be due to the fact that LAG-3 is nested (IgG2b) specific for TCR, I3 (IgG2a) specific for MHC class in the CD4 locus (21) and that its promotor may be partially II molecules were purchased from Immunotech (Marseilles, silenced when the CD4 gene is activated by proximal or distal France). BRAFB6 (IgG2b) specific for HLA-DP was obtained enhancers (22) . Here we studied LAG-3 association with from Novocastra (Newcastle, UK) and TU169 (IgG2a) specific CD3-TCR complexes and TCR co-receptors after their for HLA-DQ obtained from PharMingen (San Diego, CA). Goat engagement by using mAb or after antigen recognition that anti-mouse mAb (Texas Red-conjugated anti-IgG1 or antiallowed serial triggering of the TCR. We also tested whether IgG2a, and FITC-conjugated anti-IgG2a or anti-IgG2b) were LAG-3 co-clustered with MHC molecules following aggregafrom Southern Biotechnology Associates (Birmingham, AL). tion of the latter proteins with specific mAb.
T cells
Methods
Peripheral blood mononuclear cells were isolated from heparinized venous blood of healthy volunteer donors by FicollAntibodies Paque (Pharmacia, Piscataway, NJ) density gradient centrifugation method. T cells were stimulated by 1 µg/ml phytohemThe following mouse mAb were used at saturating concentraagglutinin (PHA-P; Murex Diagnostics, Chatillon, France) for tions. Protein A-affinity-purified OKT3 (IgG2a) specific for 3 days or for 20 days with re-stimulation every week by CD3ε, OKT4 (IgG2b) specific for CD4, OKT8 (IgG2a) specific addition of 1 µg/ml PHA and IL-2 at 10 IU/ml (Roussel Uclaf, for CD8, D1.12 (IgG2a) specific for HLA-DR, W6.32 (IgG2a) specific for MHC class I and C4C8D9 (IgG1) specific for LFARomainville, France) plus IL-12 at 2 ng/ml (R & D Systems, removed and plated on poly-L-lysine-coated glass microslides (Menzel-Glaser, Saarbrucken, Germany) and cells were fixed recognizes a decapeptide at position 286-295 of HSP70-2 mutated at position 292 (SLFEGIDI*YT, asterisk indicates the 10 min with freshly prepared PBS/4% formaldehyde. Cells were then labeled as described for antibody-induced F to I substitution). Cells were thawed and cultured for 1 day in RPMI 10% human AB serum with IL-2 at 10 IU/ml (Roussel capping. Finally, cells were mounted on slides using Immu-mount Uclaf). The autologous Epstein-Barr virus (EBV)-transformed B cell line was cultured in RPMI 10% FCS.
(Shandon, Pittsburgh, PA) as an anti-fade solution. To generate optical sections of fluorescently labeled cells, an imaging Capping and immunofluorescence microscopy system consisting of a Provis AX70 microscope (Olympus France, Rungis, France) equipped with a ϫ100 oil immersion Antibody-induced capping was performed as described (19). Briefly, PHA blasts were incubated in ice-cold RPMI/5% FCS objective lens carrying a piezoelectric Z-axis focus device, a CCD camera (Photometrics Sensys, Tucson, AZ) and a set at 5ϫ10 6 cells/ml with dialysed mAb specific for a given T cell surface molecule for 20 min, washed and incubated for 20 of computer controlled excitation filters was used. The light haze inherent to fluorescent signals was deblurred mathemin with 20 µg/ml of the appropriate FITC-or Texas Redlabeled goat anti-mouse subclass-specific Ig. Cells were then matically using the Exhaustive Photon Reassignment software (Scanalytics, Billerica, MA) (24). either fixed immediately or incubated at 37°C for 5-15 min to induce capping of the mAb-tagged cell surface receptors. Cells were washed and incubated for 20 min in ice-cold PBS Results containing 0.1% NaN 3 with mAb specific for a second T cell surface molecule, followed by incubation with FITC-or Texas TCR-induced co-capping of LAG-3 molecules Red-labeled goat anti-mouse subclass-specific Ig.
For analysis of antigen recognition-induced caps during We have recently shown that lateral association of LAG-3 and CD3ε occurs in mAb-induced CD3-capped T cells (19). This T-B cell conjugate interactions, the EBV B cells were loaded for 1 h in RPMI/5% FCS at 37°C with the mutated HSP70-2 finding does not necessarily imply that LAG-3 would co-cap with the TCR. Indeed, functional uncoupling of some TCRαβ decapeptide at 2ϫ10 -5 M. The 11C2 cytotoxic T lymphocyte TCR  LAG-3  64  48  0  75  TCR  LFA-1  69  2  3  3  TCR  CD4  52  9  11  17  CD8  LAG-3  112  108  4  96  CD8  LFA-1  42  0  2  0  CD4  LAG-3  83  22  5  26  CD4  LFA-1  52  2  0  4 a Cumulative data are presented from four antibody-induced capping experiments. Only cells that displayed a clear cap structure (with a crescent form) are scored for co-capping percentages of either the LAG-3 ϩ , CD4 ϩ or LFA-1 ϩ cell subset.
and CD3 chains occurs in activated T cells (25, 26) . Also, receptors (Fig. 2) . After mAb-induced capping of the coreceptor, 96% of LAG-3 ϩ CD8-capped cells ( Fig. 2A and anti-CD3ε mAb were found to be inefficient at inducing cocapping of the CD8 co-receptor while anti-TCRαβ mAb did Table 1 ) displayed LAG-3 co-aggregation whereas no CD8/ LFA-1 co-cap was observed ( Fig. 2B and Table 1 ). Interesinduce CD8-TCR co-capping (7). We thus studied whether LAG-3 may associate with TCR molecules on the surface of tingly, only 26% of LAG-3 ϩ CD4-capped cells displayed LAG-3 co-caps ( Fig. 2C and Table 1 ). Clustering of CD45 did not human activated T lymphocytes. TCR molecules on PHA blasts were collected into caps by cross-linking with specific induce any co-clustering of the LAG-3 molecule (not shown). mAb and the capped cells were examined by indirect immuno-LAG-3 is associated with CD3-TCR complexes following fluorescence microscopy to determine whether antigen recognition LAG-3 was co-collected with the TCR caps. Conventional fluorescence microscopy images were acquired and Anti-CD3 mAb are high-affinity ligands and their incapacity to dissociate does not allow serial triggering of TCR molecules, deblurred by using a deconvolution process with exhaustive photon reassignment. After warming the labeled cells for as observed following MHC-peptide complex recognition (4). We thus assessed whether LAG-3 may associate with CD3-5 min at 37°C, TCR molecules were collected into a cap (Fig. 1A) . A LAG-3 uniform staining was observed on TCR-TCR complexes after antigen recognition-induced TCR engagement (Fig. 3) . We analyzed CD3 caps on T-B cell uncapped cells (not shown) whereas TCR-capped cells displayed a significant co-distribution of LAG-3 with the TCR conjugates. The 11C2 CD8 ϩ CTL clone specific for a mutated HSP70 peptide expressed by the autologous renal adenocarcaps (Fig. 1A) . By contrast, no co-capping was found with LFA-1 cell surface receptors on TCR-capped cells (Fig. 1B) , cinoma cell line (23) was incubated with autologous EBVtransformed B cells pulsed with the peptide. After 30 min, as shown before with mAb-capped murine T cells (5, 12) . Data from several experiments are summarized in Table 1. some T-B cell conjugates were formed with clear CD3 caps (Fig. 3A) . By contrast, no CD3 cap was observed on conjugConversely, when the co-capping experiment was done the other way around, no co-capping of the TCR was observed ates in the absence of the HSP70 decapeptide (Fig. 3B) . On T cells activated in the presence of the peptide, LAG-3 coon LAG-3-capped cells (not shown). Overall, LAG-3 was found to be specifically co-distributed with the CD3-TCR capped with CD3 (Fig. 3A) , whereas LFA-1 did not (Fig. 3C) . Some LAG-3-capped conjugates did not display CD8 co-cap complex after mAb-induced TCR engagement on human activated T cells. We also tested two activated NK cell lines (Fig. 3D ) but CD8 co-caps were observed on most of the conjugates (example in Fig. 3DЈ ). Along the same line, most positive for CD16, a receptor known to be closely associated with CD3ζ chains (27) . Capping of CD16 molecules did not CD3-capped conjugates displayed CD8 co-caps (Fig. 3E ) even if some of them were partial (Fig. 3EЈ) . Similar results induce any co-capping of LAG-3 (data not shown).
The other MHC class II ligand, CD4, has been shown to were obtained with another renal cell carcinoma-specific CTL (3B8) primed with an intestinal carboxyl esterase nonamer be physically associated with the TCR on a cloned murine T cell line (5, 28) . We tested whether TCR engagement by peptide presented by HLA-B7 (data not shown). Specific TCR engagement of these CTL by MHC class II -autologous tumor specific mAb may induce CD4 co-clustering on human PHA blasts (Fig. 1C) . CD4 ϩ TCR-capped activated T cells discells could not be observed in this assay system due to the formation of non-specific conjugates (data not shown). played few CD4 co-caps (17%), as compared to LAG-3 cocaps (75%) on LAG-3 ϩ TCR-capped cells (Table 1) .
Altogether, these results showed that after antigen recognition, LAG-3 is co-distributed with the CD3-TCR-CD8 complex on LAG-3 is associated with CD8 following CD8 engagement by human activated T cells. specific mAb LAG-3 co-caps with MHC class II The CD3-TCR complex-associated LAG-3 molecules are MHC class II ligands (17). We analyzed whether LAG-3 was MHC class II molecules are expressed on human activated T cells. We tested whether LAG-3 and its ligands could associated on PHA blasts with the two other MHC ligands associated with TCR molecules, i.e. the CD4 and CD8 coassociate on the same cell surface (Fig. 4) . Activated peri- pheral blood lymphocytes were enriched in MHC class II ϩ explaining why the recruitment of CD4 (5,12), CD8α (7) or LAG-3 (the present study) by the corresponding mAb did not T cells by culture with PHA for 20 days. mAb-induced MHC class II engagement led to LAG-3 co-clustering ( Fig. 4A and lead to TCR-CD3 co-capping, while TCR engagement which is followed by the recruitment of rafts at its site leads to co- Table 2 ). This was observed for all three subclasses, i.e. DR, DP or DQ molecules ( Fig. 4A and Table 2 ). Table 2 summarizes capping of these MHC ligands. CD45 is another molecule not included in raft microdomains (31) and its capping does data obtained in several experiments and indicates that the majority of MHC class II-capped cells also had LAG-3 conot induce LAG-3 co-caps (the present study). Also, this hypothesis explains why co-immunoprecipitation experiments caps (an example in Fig. 4B ). Few LAG-3 co-caps were also observed on MHC class I-capped cells (Fig. 4C and Table  looking for LAG-3/CD3ζ or LAG-3/DR associations in the presence of different detergents were negative. 2). Overall, these results clearly show that LAG-3 and MHC class II molecules co-clustered on the surface of activated
We observed that LAG-3 was preferentially associated with the CD8 rather than the CD4 co-receptor at the cell surface. T lymphocytes following mAb-induced capping.
Differences between the two T cell subsets have also been found when studying LAG-3 expression and its up-regulation Discussion with cytokines. The expression of LAG-3 is 7 times higher on CD8 ϩ than CD4 ϩ T cells (20). Up-regulation of LAG-3 Surface receptor patching and capping are initial events in signal transduction in lymphocytes during which numerous expression by IL-2 plus IL-12 is higher on CD8 ϩ than CD4 ϩ T cells as well (22) . This phenomenon could be explained by proteins migrate to a single pole of the cell after stimulation with antigen or other proliferative stimuli. In the present study, the sharing of some regulatory elements common to LAG-3 and CD4 genes on chromosome 12p13 where both genes co-capping experiments revealed that LAG-3, a ligand for MHC class II, is co-distributed with CD3-TCR complex and are nested (21) , regulatory elements which could partially silence the LAG-3 promotor when the CD4 promotor is CD8 molecules after their engagement by mAb as well as after antigen recognition. Unlike co-precipitation studies which activated (22) . Unbalanced LAG-3 expression is unlikely to have introduced a bias in our analysis of LAG-3 association rely on molecules being able to maintain associations after solubilization in detergents, co-capping studies identify either with co-receptors because we have chosen to analyze only cells with high LAG-3 expression levels. It is possible that a interactions which occur directly or indirectly between molecules in physiological conditions, or only a clustering of these close association between LAG-3, CD3-TCR complexes and CD8 reflects a distinct and predominant functional role of molecules in raft microdomains which do not necessarily involve protein interactions.
LAG-3 on CD8 ϩ T cells. In addition to the report of a negative regulatory role of LAG-3 on TCR signaling and to a Using different detergents, such as Brij96, CHAPS, Triton X100 or NP-40, we have been unable to detect any association LAG-3-mediated down-regulation of TCR expression (19), LAG-3-specific mAb, either as whole IgG or as Fab fragments, between LAG-3 and either CD3ζ or DR molecules. It may therefore be speculated that the supramolecular assemblies that inhibit LAG-3/MHC class II interactions were shown to induce prolonged activation and proliferation of CD4 ϩ antigendescribed here between LAG-3 and both CD3/CD8 and MHC class II molecules are based on the residence of the relevant specific T cell clones following antigen recognition (33) . These results suggest that LAG-3 exerts a negative regulatory role molecules within a limited area such as detergent insoluble sphingolipid-cholesterol-rich rafts. Such rafts are known to on antigen-dependent stimulation via its association with CD3-TCR complexes. However, LAG-3-specific mAb have concentrate many proteins involved in early events of T cell activation, such as CD4, CD8, lck, fyn, cbl or ras (29) (30) (31) . By not been found to date to alter the proliferation, cytotoxic or cytokine responses of CD8 ϩ T cells (33 and unpublished contrast, CD3-TCR complexes are excluded from these raft microdomains and enter them only following TCR engagement results). MHC class II are expressed preferentially on professional to interact with MHC ligands such as CD4 (32) . Similarly to CD4, LAG-3 may be concentrated in detergent-insoluble rafts, APC. Results of the present study suggest that a ligand of MHC 
